Background and aims: limited evidence is available to guide hepatologists regarding endoscopic surveillance of esophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs). Methods: patients were divided into 2 groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favorable Baveno VI status) and Group 2 (335, 78.5%, unfavorable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations. Results: 4.3% of group 1 patients showed baseline EV compared with 30.1% of group 2 patients (p<0.0001). No patients belonging to group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in group 2 patients (p= 0.02); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 (p= 0.001). Improvement in Baveno VI status was observed in 118/335 (35.2%, p<0.0001) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up. Conclusions: HCV-positive cirrhotic patients cured by DAAs showing baseline favorable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavorable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.

Screening and surveillance of esophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct acting antiviral agents

Ciancio, Alessia
First
;
Ribaldone, Davide Giuseppe;Salamone, Rossella;Caronna, Stefania;Giordanino, Chiara;Rolle, Emanuela;Sacco, Marco;De Angelis, Claudio;Saracco, Giorgio Maria
Last
2022-01-01

Abstract

Background and aims: limited evidence is available to guide hepatologists regarding endoscopic surveillance of esophageal varices (EV) in Hepatitis C Virus (HCV)-positive cirrhotic patients achieving a sustained virologic response. To address these issues, we conducted a long-term prospective study on 427 HCV-positive cirrhotic patients successfully treated by Direct Antiviral Agents (DAAs). Methods: patients were divided into 2 groups according to their baseline Baveno VI status: Group 1 (92, 21.5%, favorable Baveno VI status) and Group 2 (335, 78.5%, unfavorable Baveno VI status). Each patient underwent baseline endoscopy and was endoscopically monitored for a median follow-up of 65.2 months according to Baveno VI recommendations. Results: 4.3% of group 1 patients showed baseline EV compared with 30.1% of group 2 patients (p<0.0001). No patients belonging to group 1 without baseline EV developed EV at follow-up endoscopy compared with 6.5% in group 2 patients (p= 0.02); 69/107 (64.5%) patients with baseline EV showed small varices. During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 (p= 0.001). Improvement in Baveno VI status was observed in 118/335 (35.2%, p<0.0001) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up. Conclusions: HCV-positive cirrhotic patients cured by DAAs showing baseline favorable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients having unfavorable Baveno VI status without baseline EV who improve their status may suspend further endoscopic surveillance.
1
11
Ciancio, Alessia; Ribaldone, Davide Giuseppe; Salamone, Rossella; Bruno, Mauro; Caronna, Stefania; Debernardi Venon, Wilma; Giordanino, Chiara; Mondardini, Alessandra; Musso, Alessandro; Pennazio, Marco; Rolle, Emanuela; Sacco, Marco; Sprujevnik, Tatiana; De Angelis, Claudio; Saracco, Giorgio Maria
File in questo prodotto:
File Dimensione Formato  
LIVint-21-01681.R2_Proof_hi (1).pdf

Accesso aperto con embargo fino al 04/03/2023

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1844821
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact